ArticleBlood2009
Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- The Complex Role of Mast Cells in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways.Frontiers in immunology · 2022Pooled it
- Pooled it
- Mast cell-derived MIF Polarizes Th17 cells to drive lung adenocarcinoma progression.Cancer immunology, immunotherapy : CII · 2026Article
- Advances in immunological research on male infertility.Frontiers in reproductive health · 2026Review
- Review
- Mast Cell Association with the Microenvironment of a Phosphaturic Mesenchymal Tumour Secreting Fibroblast Growth Factor 23.Medical sciences (Basel, Switzerland) · 2025Article
- The anionic surfactant Sodium Dodecyl Benzene Sulfonate alleviates inflammatory responses in atopic dermatitis via NFκB/MAPK pathways in a STAT3-dependent manner.Scientific reports · 2025Article
- Blood-CSF barrier clearance of ABC transporter substrates is suppressed by interleukin-6 in lupus choroid plexus spheroids.Fluids and barriers of the CNS · 2025Article
- Pan-cancer analysis shows that TNFSF4 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types including liver cancer.BMC cancer · 2025Article
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment.Frontiers in immunology · 2025Review
- Mast cell metabolism in cancer: an underexplored frontier demanding more attention.Frontiers in immunology · 2025Review
- Synovial mast cells and osteoarthritis: Current understandings and future perspectives.Heliyon · 2024Review
- Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy.Pharmaceutics · 2023Review
- Blockade of IL-6 signaling alleviates atherosclerosis inNature cardiovascular research · 2023Article
- Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data.Life (Basel, Switzerland) · 2023Review
- Revisiting regulatory T cells as modulators of innate immune response and inflammatory diseases.Frontiers in immunology · 2023Review
- Mast Cells and Interleukins.International journal of molecular sciences · 2022Review
- Controversial role of mast cells in NSCLC tumor progression and angiogenesis.Thoracic cancer · 2022Review
- Somatic-Immune Cells Crosstalk In-The-Making of Testicular Immune Privilege.Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of inflammatory diseases implies inactivation of regulatory T (Treg) cells through mechanisms that still are largely unknown. Here we showed that mast cells (MCs), an early source of inflammatory mediators, are able to counteract Treg inhibition over effector T cells. To gain insight into the molecules involved in their interplay, we set up an in vitro system in which all 3 cellular components were put in contact. Reversal of Treg suppression required T cell-derived interleukin-6 (IL-6) and the OX40/OX40L axis. In the presence of activated MCs, concomitant abundance of IL-6 and paucity of Th1/Th2 cytokines skewed Tregs and effector T cells into IL-17-producing T cells (Th17). In vivo analysis of lymph nodes hosting T-cell priming in experimental autoimmune encephalomyelitis revealed activated MCs, Tregs, and Th17 cells displaying tight spatial interactions, further supporting the occurrence of an MC-mediated inhibition of Treg suppression in the establishment of Th17-mediated inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.